Gary Maassen
Internal Medicine · Saint Louis, MONPI 1831170968
Payments from drug & device makers
Across 217 payments — averaging $15.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$452
- Novo Nordisk$389
- Johnson & Johnson$249
- Sanofi-aventis U.S. LLC$232
- GSK$214
- Boehringer Ingelheim$188
- plus $2K from 24 others
What the payments were for
- Food & beverage$3,293100%
- Education$50%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 32 | $452 |
| Novo Nordisk | 31 | $389 |
| Johnson & Johnson | 16 | $249 |
| Sanofi-aventis U.S. LLC | 14 | $232 |
| GSK | 14 | $214 |
| Boehringer Ingelheim | 11 | $188 |
| AstraZeneca | 12 | $168 |
| E.r. Squibb & Sons, L.L.C. | 9 | $142 |
| Amarin Pharma, Inc. | 9 | $137 |
| Lilly USA, LLC | 8 | $135 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 8 | $117 |
| Merck | 8 | $116 |
| Astellas Pharma US Inc | 7 | $112 |
| AbbVie | 5 | $111 |
| Amgen | 7 | $105 |
| Novartis | 5 | $78 |
| Bayer | 3 | $48 |
| Otsuka America Pharmaceutical, Inc. | 2 | $39 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $34 |
| Kowa Pharmaceuticals America, Inc. | 2 | $34 |
| Xeris Pharmaceuticals, Inc. | 1 | $25 |
| Endo Pharmaceuticals Inc. | 2 | $24 |
| Idorsia Pharmaceuticals US Inc | 1 | $23 |
| Biohaven Pharmaceuticals, Inc. | 1 | $23 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $21 |
| Sunovion Pharmaceuticals Inc. | 1 | $19 |
| Circassia Inc. | 1 | $18 |
| Sumitomo Pharma America, Inc. | 1 | $16 |
| Teva Pharmaceuticals USA, Inc. | 1 | $16 |
| Dexcom, Inc. | 1 | $14 |
How this compares
$3,298 in reported general payments places this provider in the 85th percentile of 2,097 internal medicine providers in Missouri.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 83 | $66,543 |
| FarxigaDapagliflozin Propanediol | 21 | $21,054 |
| XareltoRivaroxaban | 32 | $20,654 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 21 | $20,153 |
| OzempicSemaglutide | 15 | $15,916 |
| JardianceEmpagliflozin | 15 | $15,756 |
| MounjaroTirzepatide | 11 | $11,407 |
| Breo ElliptaFluticasone/Vilanterol | 24 | $9,510 |
| MyrbetriqMirabegron | 18 | $8,849 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 12 | $7,994 |
| Atorvastatin Calcium | 272 | $3,237 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 13 | $2,496 |
| Metoprolol Succinate | 119 | $2,044 |
| Rosuvastatin Calcium | 91 | $1,830 |
| Levothyroxine Sodium | 85 | $1,656 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $452 | $66,54383 claims |
| AstraZenecaFarxiga | $168 | $21,05421 claims |
| Johnson & JohnsonXarelto | $249 | $20,65432 claims |
| GSKBreo Ellipta, Trelegy Ellipta | $214 | $17,50436 claims |
| Novo NordiskOzempic | $389 | $15,91615 claims |
| Boehringer IngelheimJardiance | $188 | $15,75615 claims |
| Lilly USA, LLCMounjaro | $135 | $11,40711 claims |
| Astellas Pharma US IncMyrbetriq | $112 | $8,84918 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,097 internal medicine providers in Missouri.
Other internal medicine in Saint Louis
- Michael ReschakSaint Louis$3.1M
- David PrelutskySaint Louis$575K
- Danish JabbarSaint Louis$510K
- Hany SalamaSaint Louis$279K
- Lauren LevineSaint Louis$264K
- Brij VaidSaint Louis$213K
- Vinay KamatSaint Louis$191K
- Tracy NorfleetSaint Louis$132K
- Paul OlivoSaint Louis$98K
- Priyanka RavalSaint Louis$95K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.